% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jamaladdin:277488,
      author       = {N. Jamaladdin$^*$ and R. Sigaud$^*$ and D. Kocher$^*$ and
                      A. Kolodziejczak$^*$ and L. Nonnenbroich$^*$ and J.
                      Ecker$^*$ and D. Usta$^*$ and J. Benzel and H. Peterziel$^*$
                      and K. W. Pajtler and C. M. van Tilburg$^*$ and I. Oehme$^*$
                      and O. Witt$^*$ and T. Milde$^*$},
      title        = {{K}ey pharmacokinetic parameters of 74 pediatric anticancer
                      drugs providing assistance in preclinical studies.},
      journal      = {Clinical pharmacology $\&$ therapeutics},
      volume       = {114},
      number       = {4},
      issn         = {0009-9236},
      address      = {Hoboken, NJ},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2023-01401},
      pages        = {904-913},
      year         = {2023},
      note         = {#EA:B310#LA:B310# /2023 Oct;114(4):904-913},
      abstract     = {Novel drug treatments for pediatric cancer patients are
                      urgently needed. Success of drug development in pediatric
                      oncology has been promising, but many drugs still fail in
                      translation from preclinical to clinical phases. To increase
                      the translational potential, several improvements have been
                      implemented, including the use of clinically achievable
                      concentrations in the drug testing phase. While
                      pharmacokinetic (PK) parameters of numerous investigated
                      drugs are published, a comprehensive PK overview of the most
                      common drugs in pediatric oncology could guide preclinical
                      trial design and improve the translatability into clinical
                      trials. A mini literature review was conducted for PK
                      parameters of 74 anticancer drugs, from the drug sensitivity
                      profiling library of the INdividualized Therapy FOr Relapsed
                      Malignancies in Childhood (INFORM) registry. PK data in the
                      pediatric population were reported and complemented by adult
                      parameters when no pediatric data was available. In
                      addition, blood-brain barrier (BBB)-penetration assessment
                      of drugs was provided by using the BBB-Score. Cmax was
                      available for 73 $(97\%),$ AUC for 69 $(92\%),$ PPB for 66
                      $(88\%),$ T1/2 for 57 $(76\%),$ Tmax for 54 $(72\%),$ Cl for
                      52 $(69\%),$ Vd for 37 $(49\%),$ Ctrough for 21 $(28\%)$ and
                      Css for 4 $(5\%)$ of drugs. Pediatric PK data were available
                      for 48 $(65\%)$ drugs. We provide a comprehensive review of
                      PK data for 74 drugs studied in pediatric oncology. This
                      data set can serve as a reference to design experiments more
                      closely mimicking drug PK conditions in patients, and may
                      thereby increase the probability of successful clinical
                      translation.},
      cin          = {B310 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B310-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37441736},
      doi          = {10.1002/cpt.3002},
      url          = {https://inrepo02.dkfz.de/record/277488},
}